Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States
Author:
Publisher
Wiley
Subject
Hematology
Reference9 articles.
1. Secondary Iron Overload
2. Results of Long-Term Iron-Chelating Therapy
3. Efficacy of Deferoxamine in Preventing Complications of Iron Overload in Patients with Thalassemia Major
4. Survival in Medically Treated Patients with Homozygous β-Thalassemia
5. Iron-Chelating Therapy and the Treatment of Thalassemia
Cited by 29 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Economic burden of Thalassemia treatment: An analysis from the Vietnam Social Security perspective;PLOS ONE;2023-11-27
2. Economic and clinical burden of managing transfusion-dependent β-thalassemia in the United States;Journal of Medical Economics;2023-07-24
3. The patient perspective: The struggles of living with thalassemia as an adult;Annals of the New York Academy of Sciences;2023-07-19
4. Medical and Non-medical Costs of Sickle Cell Disease and Treatments from a US Perspective: A Systematic Review and Landscape Analysis;PharmacoEconomics - Open;2022-04-26
5. Healthcare resource utilization and direct costs of transfusion-dependent thalassemia patients in Dubai, United Arab Emirates: a retrospective cost-of-illness study;BMC Health Services Research;2022-03-05
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3